Alembic Pharmaceuticals has received final USFDA approval for two anti-hypertension tablets – olmesartan medoxomil tablets, 5 mg, 20 mg, and 40 mg and olmesartan medoxomil with hydrochlorothiazide tablets 20/12.5mg, 40/12.5mg and 40/25mg. The approved products are therapeutically equivalent to the reference listed drug products Benicar and Benicar HCT of Daiichi Sankyo, which is used for the treatment of hypertension. According to IMS sales data for the 12-month period ended December 2016, the products Benicar and Benicar HCT have an estimated market size of $1.8 billion.
Company Profile : Alembic Pharmaceuticals Ltd
Leave a Reply